Abstract
Neurodegeneration in Huntington disease is described by neuronal loss in which the probability of cell death remains constant with time1. However, the quantitative connection between the kinetics of cell death and the molecular mechanism initiating neurodegeneration remains unclear. One hypothesis is that nucleation of protein aggregates containing exon I fragments of the mutant huntingtin protein (mhttex1), which contains an expanded polyglutamine region in patients with the disease, is the explanation for the infrequent but steady occurrence of neuronal death, resulting in adult onset of the disease2. Recent in vitro evidence suggests that sufficiently long polyglutamine peptides undergo a unimolecular conformational change to form a nucleus that seeds aggregation3. Here we use this nucleation mechanism as the basis to derive a stochastic mathematical model describing the probability of aggregate formation in cells as a function of time and mhttex1 protein concentration, and validate the model experimentally. These findings suggest that therapeutic strategies for Huntington disease predicated on reducing the rate of mhttex1 aggregation need only make modest reductions in huntingtin expression level to substantially increase the delay time until aggregate formation.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Clarke, G. et al. A one-hit model of cell death in inherited neuronal degenerations. Nature 406, 195–199 (2000).
Perutz, M.F. & Windle, A.H. Cause of neural death in neurodegenerative diseases attributable to expansion of glutamine repeats. Nature 412, 143–144 (2001).
Chen, S., Ferrone, F.A. & Wetzel, R. Huntington's disease age-of-onset linked to polyglutamine aggregation nucleation. Proc. Natl. Acad. Sci. USA 99, 11884–11889 (2002).
DiFiglia, M. et al. Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. Science 277, 1990–1993 (1997).
Arrasate, M., Mitra, S., Schweitzer, E.S., Segal, M.R. & Finkbeiner, S. Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death. Nature 431, 805–810 (2004).
Bence, N.F., Sampat, R.M. & Kopito, R.R. Impairment of the ubiquitin-proteasome system by protein aggregation. Science 292, 1552–1555 (2001).
Garcia, M., Charvin, D. & Caboche, J. Expanded huntingtin activates the c-Jun terminal kinase/c-Jun pathway prior to aggregate formation in striatal neurons in culture. Neuroscience 127, 859–870 (2004).
Meriin, A.B. et al. Huntington toxicity in yeast model depends on polyglutamine aggregation mediated by a prion-like protein Rnq1. J. Cell Biol. 157, 997–1004 (2002).
Saudou, F., Finkbeiner, S., Devys, D. & Greenberg, M.E. Huntingtin acts in the nucleus to induce apoptosis but death does not correlate with the formation of intranuclear inclusions. Cell 95, 55–66 (1998).
Nucifora, F.C., Jr. et al. Interference by huntingtin and atrophin-1 with cbp-mediated transcription leading to cellular toxicity. Science 291, 2423–2428 (2001).
Lomakin, A., Teplow, D.B., Kirschner, D.A. & Benedek, G.B. Kinetic theory of fibrillogenesis of amyloid β-protein. Proc. Natl. Acad. Sci. USA 94, 7942–7947 (1997).
Gillespie, D.T. Exact stochastic simulation of coupled chemical reactions. J. Phys. Chem. 81, 2340–2361 (1977).
Hofrichter, J., Ross, P.D. & Eaton, W.A. Kinetics and mechanism of deoxyhemoglobin S gelation: a new approach to understanding sickle cell disease. Proc. Natl. Acad. Sci. USA 71, 4864–4868 (1974).
Jarrett, J.T. & Lansbury, P.T., Jr. Seeding “one-dimensional crystallization” of amyloid: a pathogenic mechanism in Alzheimer's disease and scrapie? Cell 73, 1055–1058 (1993).
Cattaneo, E. & Conti, L. Generation and characterization of embryonic striatal conditionally immortalized ST14A cells. J. Neurosci. Res. 53, 223–234 (1998).
Arrasate, M. & Finkbeiner, S. Automated microscope system for determining factors that predict neuronal fate. Proc. Natl. Acad. Sci. USA 102, 3840–3845 (2005).
Renshaw, E. Modelling Biological Populations in Space and Time (Cambridge University Press, Cambridge, UK, 1991).
Szabo, A. Fluctuations in the polymerization of sickle hemoglobin. A simple analytic model. J. Mol. Biol. 199, 539–542 (1988).
Cao, Z. & Ferrone, F.A. Homogeneous nucleation in sickle hemoglobin: stochastic measurements with a parallel method. Biophys. J. 72, 343–352 (1997).
Bhattacharyya, A.M., Thakur, A.K. & Wetzel, R. Polyglutamine aggregation nucleation: thermodynamics of a highly unfavorable protein folding reaction. Proc. Natl. Acad. Sci. USA 102, 15400–15405 (2005).
Shtilerman, M.D., Ding, T.T. & Lansbury, P.T., Jr. Molecular crowding accelerates fibrillization of α-synuclein: could an increase in the cytoplasmic protein concentration induce Parkinson's disease? Biochemistry 41, 3855–3860 (2002).
Hatters, D.M., Minton, A.P. & Howlett, G.J. Macromolecular crowding accelerates amyloid formation by human apolipoprotein C–II. J. Biol. Chem. 277, 7824–7830 (2002).
Ivanova, M., Jasuja, R., Kwong, S., Briehl, R.W. & Ferrone, F.A. Nonideality and the nucleation of sickle hemoglobin. Biophys. J. 79, 1016–1022 (2000).
Minton, A.P. The influence of macromolecular crowding and macromolecular confinement on biochemical reactions in physiological media. J. Biol. Chem. 276, 10577–10580 (2001).
Slow, E.J. et al. Absence of behavioral abnormalities and neurodegeneration in vivo despite widespread neuronal huntingtin inclusions. Proc. Natl. Acad. Sci. USA 102, 11402–11407 (2005).
Scherzinger, E. et al. Huntingtin-encoded polyglutamine expansions form amyloid-like protein aggregates in vitro and in vivo. Cell 90, 549–558 (1997).
Zhang, X. et al. A potent small molecule inhibits polyglutamine aggregation in Huntington's disease neurons and suppresses neurodegeneration in vivo. Proc. Natl. Acad. Sci. USA 102, 892–897 (2005).
Kazantsev, A. et al. A bivalent Huntingtin binding peptide suppresses polyglutamine aggregation and pathogenesis in Drosophila. Nat. Genet. 30, 367–376 (2002).
Colby, D.W. et al. Potent inhibition of huntingtin aggregation and cytotoxicity by a disulfide bond-free single-domain intracellular antibody. Proc. Natl. Acad. Sci. USA 101, 17616–17621 (2004).
Gu, X. et al. Pathological cell-cell interactions elicited by a neuropathogenic form of mutant Huntingtin contribute to cortical pathogenesis in HD mice. Neuron 46, 433–444 (2005).
Harper, S.Q. et al. RNA interference improves motor and neuropathological abnormalities in a Huntington's disease mouse model. Proc. Natl. Acad. Sci. USA 102, 5820–5825 (2005).
Nance, M.A. & Myers, R.H. Juvenile onset Huntington's disease—clinical and research perspectives. Ment. Retard. Dev. Disabil. Res. Rev. 7, 153–157 (2001).
Gusella, J.F. & MacDonald, M.E. Molecular genetics: unmasking polyglutamine triggers in neurodegenerative disease. Nat. Rev. Neurosci. 1, 109–115 (2000).
Wexler, N.S. et al. Venezuelan kindreds reveal that genetic and environmental factors modulate Huntington's disease age of onset. Proc. Natl. Acad. Sci. USA 101, 3498–3503 (2004).
Squitieri, F. et al. Homozygosity for CAG mutation in Huntington disease is associated with a more severe clinical course. Brain 126, 946–955 (2003).
Krobitsch, S. & Lindquist, S. Aggregation of huntingtin in yeast varies with the length of the polyglutamine expansion and the expression of chaperone proteins. Proc. Natl. Acad. Sci. USA 97, 1589–1594 (2000).
Larson, H.J. Introduction to Probability Theory and Statistical Inference (Wiley, New York, 1982).
Rosenblatt, A., Ranen, N.G., Nance, M.A. & Paulsen, J.S. Physician's Guide to the Management of Huntington's Disease 2nd edn. http://www.hdsa.org/site/DocServer/Physicians_Guide_JAT_conversion_color_5-4-05.pdf?docID=241 (Huntington's Disease Society of America, New York, 1999).
Acknowledgements
We thank the US National Science Foundation Graduate Research Fellowship program (D.W.C.), the Hereditary Disease Foundation and the HighQ Foundation for financial support of this work.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Supplementary information
Supplementary Fig. 1
Concentration of httex1Q72-GFP in individual cells during the 18 hour period following sorting, measured by time-lapse fluorescence microscopy. (PDF 456 kb)
Rights and permissions
About this article
Cite this article
Colby, D., Cassady, J., Lin, G. et al. Stochastic kinetics of intracellular huntingtin aggregate formation. Nat Chem Biol 2, 319–323 (2006). https://doi.org/10.1038/nchembio792
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/nchembio792
This article is cited by
-
Transglutaminase 2 has opposing roles in the regulation of cellular functions as well as cell growth and death
Cell Death & Disease (2016)
-
TDP-43 Proteinopathy and ALS: Insights into Disease Mechanisms and Therapeutic Targets
Neurotherapeutics (2015)
-
Proteostasis of polyglutamine varies among neurons and predicts neurodegeneration
Nature Chemical Biology (2013)
-
An in vitro perspective on the molecular mechanisms underlying mutant huntingtin protein toxicity
Cell Death & Disease (2012)
-
Techniques for monitoring protein misfolding and aggregation in vitro and in living cells
Korean Journal of Chemical Engineering (2012)